The role of technetium-99m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid
- 1 November 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 60 (719) , 1089-1092
- https://doi.org/10.1259/0007-1285-60-719-1089
Abstract
In order to assess the role of 99Tcm pentavalent dimercaptosuccinic acid (99Tcm (V)DMSA) scanning in the management of patients with medullary carcinoma of the thyroid, we imaged 10 patients with histologically proven disease. Nine of the 10 patients were scanned after removal of the primary tumour, but with symptomatic or biochemical evidence of recurrence. One patient was imaged prior to thyroidectomy. In eight of the 10 patients 99m(V)DMSA successfully identified tumour deposits, and it has been shown in this study to be a cheap, convenient radiopharmaceutical for studying this group of patients, producing high-quality images with low radiation doses, and contributing significantly to patient management.This publication has 3 references indexed in Scilit:
- Imaging of Soft Tissue Tumors with Tc(V)-99m Dimercaptosuccinic AcidClinical Nuclear Medicine, 1984
- Radiotracer Uptake in Medullary Carcinoma of the ThyroidClinical Nuclear Medicine, 1980
- Sipple's Syndrome: Medullary Thyroid Carcinoma, Pheochromocytoma, and Parathyroid DiseaseAnnals of Internal Medicine, 1973